UK markets closed
  • NIKKEI 225

    27,927.37
    -102.20 (-0.36%)
     
  • HANG SENG

    23,349.38
    -417.31 (-1.76%)
     
  • CRUDE OIL

    69.64
    +3.38 (+5.10%)
     
  • GOLD FUTURES

    1,779.70
    -4.20 (-0.24%)
     
  • DOW

    35,219.09
    +639.01 (+1.85%)
     
  • BTC-GBP

    37,085.91
    +91.40 (+0.25%)
     
  • CMC Crypto 200

    1,270.76
    +10.60 (+0.84%)
     
  • ^IXIC

    15,225.88
    +140.41 (+0.93%)
     
  • ^FTAS

    4,117.60
    +58.28 (+1.44%)
     

Denali Therapeutics Inc. (NASDAQ:DNLI) Analysts Are Reducing Their Forecasts For This Year

  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Market forces rained on the parade of Denali Therapeutics Inc. (NASDAQ:DNLI) shareholders today, when the analysts downgraded their forecasts for this year. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting the analysts have soured majorly on the business.

Following the downgrade, the consensus from twelve analysts covering Denali Therapeutics is for revenues of US$83m in 2021, implying a painful 77% decline in sales compared to the last 12 months. Following this this downgrade, earnings are now expected to tip over into loss-making territory, with the analysts forecasting losses of US$2.04 per share in 2021. However, before this estimates update, the consensus had been expecting revenues of US$98m and US$1.66 per share in losses. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase.

See our latest analysis for Denali Therapeutics

earnings-and-revenue-growth
earnings-and-revenue-growth

The consensus price target was broadly unchanged at US$86.10, perhaps implicitly signalling that the weaker earnings outlook is not expected to have a long-term impact on the valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Denali Therapeutics at US$108 per share, while the most bearish prices it at US$60.00. This shows there is still some diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We would highlight that sales are expected to reverse, with a forecast 95% annualised revenue decline to the end of 2021. That is a notable change from historical growth of 67% over the last three years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 9.4% per year. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Denali Therapeutics is expected to lag the wider industry.

The Bottom Line

The most important thing to take away is that analysts increased their loss per share estimates for this year. Unfortunately analysts also downgraded their revenue estimates, and industry data suggests that Denali Therapeutics' revenues are expected to grow slower than the wider market. We're also surprised to see that the price target went unchanged. Still, deteriorating business conditions (assuming accurate forecasts!) can be a leading indicator for the stock price, so we wouldn't blame investors for being more cautious on Denali Therapeutics after the downgrade.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Denali Therapeutics going out to 2023, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting